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Abstract 
The objective of this meeting was to discuss ongoing initiatives in Botswana since February 2016 to 
improve antibiotic use. Subsequently, use the findings to refine national and local action plans. There 
was a high rate of antibiotic prescribing among ambulatory care patients in the public sector (42.7%) 
as well as for patients with URTIs in the private sector (72.9%). Prophylactic antibiotics were given to 
73.3% of surgical patients to reduce surgical site infections (SSIs) in a leading tertiary hospital in 
Botswana; however, SSIs at 9% of patients can be reduced further with better timing of antibiotic 
prophylaxis. To date, 773 patients have been enrolled into the national point prevalence study. 
Highlighted concerns included limited ordering and use of sensitivity tests despite functional 
laboratories, as well as concerns with missed doses of antibiotics across most hospitals. Activities are 
ongoing across sectors to address these concerns. 
 
1. Introduction 
There is a high burden of infectious diseases in Africa, especially sub-Sahara Africa, resulting in 
appreciable increases in antibiotic utilization in recent years, exacerbated by the ability of patients to 
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self-purchase antibiotics (1, 2). An appreciable proportion of antibiotic use is known to be irrational 
enhancing antimicrobial resistance (AMR); with AMR known to increase morbidity, mortality and costs 
(2-4). Irrational antibiotic prescribing includes the routine prescribing and dispensing of antibiotics for 
upper respiratory tract infections (URTIs), most of which are viral in origin (1, 4, 5). These concerns 
were drivers behind the first meeting held in Botswana in February 2016 to develop a deeper 
understanding of current antibiotic utilization, following the availability of antibiotic guidelines in 
Botswana, as well as plan for the future (3), whilst recognising that guidelines are not always followed, 
and there are concerns with the extent of empiric use of antibiotics and variable use of sensitivity 
analyses in Botswana (6, 7). The lack of adherence to guidelines is not helped by their variable 
availability (8). Activities recommended in February 2016 included the introduction of a national 
antibiotic point prevalence study (PPS), building on initiatives in Europe and globally (3).  
 
2. Objectives and Rationale 
The objective of this symposium RQµ(QKDQFLQJWKHDSSURSULDWHXVHRIDQWLELRWLFVLQ%RWVZDQD¶KHOGDW
the University of Botswana, 24 October 2017, was to present and discuss ongoing initiatives and 
findings since February 2016, and use these to further improve antimicrobial prescribing in Botswana 
as part of the ongoing National Action Plan (NAP) for antimicrobials. The latter involves Dr. 
Tiroyakgosi and her team at the Ministry of Health and Wellness in Botswana, together with the 
Ministry of Agriculture Development and Food Security and the Ministry of Land Management, Water 
and Sanitation Services, to develop the Botswana Antimicrobial NAP with input from across 
Botswana. The prepared draft is currently being circulated among the key stakeholder Ministries in 
Botswana, and will be updated in the future based on pertinent research findings. 
 
The meeting was opened by the Dean of the Faculty of Medicine, University of Botswana, which was 
followed by Emily Summers, Deputy High Commissioner from the British High Commission 
(http://muria.mandela.ac.za/Botswana-Symposium-October-2017). Emily commented that the 
increase in AMR in recent years was a major concern to the British Government, resulting in 
publications to try and document its impact in terms of mortality, security and costs if not addressed 
(9). This builds on World Health Organisation (WHO) initiatives highlighting the impact of AMR, with 
the recognized need to develop global action plans (10). In addition, the UK Government is 
committing considerable funds (GB£165 million over 5 years) to help address this issue. This includes 
core funding to WHO and other multilateral organizations addressing resistance rates and the over 
use of antibiotics in Botswana. Initiatives such as this symposium were also welcome ways to cross 
sectors and seek to enhance the appropriate use of antibiotics in veterinary medicine, which is rapidly 
becoming a public health issue. 
 
Brian Godman from the Karolinska Institute and Strathclyde University gave a brief summary of the 
activities of MURIA (Medicines Utilisation Research in Africa) group following the first meeting in 
South Africa in January 2015 to improve the rational use of medicines (RUM) in Africa (11). Since 
then, there have been three annual meetings in addition to the February 2016 meeting (3, 7, 12) 
(http://muria.mandela.ac.za/), as well as numerous publications in peer-reviewed journals (40 by 
October 2017). The July 2016 meeting included discussions to adapt the PPS forms following 
feedback of the pilot study (12). The adapted PPS forms are already being used across Africa, with 
the findings being part of NAPs (13-15). This Pan-African co-operation will continue benefiting all in 
Africa. 
  
3. Plenary Session 
Yohana Mashalla, Professor and Dean at the University of Botswana, discussed the findings of a 
study among public Primary Healthcare facilities (PHCs) in Botswana to assess the prescribing of 
medicines against WHO/ International Network for Rational Use of Drugs (INRUD) indicators and 
made suggestions for the future. There was an average of 2.8 medicines per prescription, with a high 
rate of INN prescribing and compliance with the Botswana Essential Drugs List (EDL) at 78.6% of and 
96.1% respectively (2). However, the rate of antibiotic prescribing was high at 42.7% with a number of 
patients having two and three antibiotics respectively. Amoxicillin accounted for 28.4% of systemic 
antibiotic use with Metronidazole second at 14.4%. Encouragingly, there was low use of co-amoxiclav 
(0.3%), third generation cephalosporins (9.8%) and no prescribing of fluoroquinolones. The majority of 
indications for antibiotic prescriptions were according to ICD classification; however, there is room for 
improvement. Future strategies could include developing pertinent quality indicators to more 
appropriately assess the quality of antibiotic prescribing among PHCs given the high burden of 
gynaecological and sexually transmitted infections in Botswana (2).  
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Matshediso Matome, head of Managed Care at the Associated Fund Administrators which 
administers two large medical aid funds in Botswana, discussed recent findings among the private 
sector in Botswana regarding antibiotic utilisation to treat patients with URTIs (16). The data included 
311,953 acute prescription encounters incorporating prescriptions dispensed by private GPs (49%), 
Community Pharmacists (30%), Hospital Pharmacists (16%) and Medical Specialists (3.9%). Only 
12% of pharmacy claims had a specific ICD10 code. Overall, there were 216,256 encounters of which 
17.4% were for URTIs and 72.9% of these had at least one antibiotic dispensed. This is similar to the 
high rates of inappropriate prescribing for URTIs in the private sector in other countries (17, 18). The 
prescribing of antibiotics for URTIs  is seen as inappropriate given that a high percentage of URTIs 
are viral in original (1, 5, 19) and there is limited effectiveness of antibiotics in this condition (20). The 
beta-lactams dominated the antibiotics prescribed and dispensed (J01C and J01D) at 81.4%, followed 
by the macrolides at 10.7% (J01F). Fluorquinolone use was low (J01M) at 0.5%. However, within the 
beta lactam penicillins, combination penicillins such as co-amoxiclav dominated at 84.9% of penicillin 
use despite concerns about their overuse. Given the considerable concerns regarding the high rate of 
inappropriate prescribing, future suggestions included strengthening current indicators to include new 
quality indicators, educational programmes among private medical practitioners and pharmacists, as 
well as utilising their help with designing future studies.  
 
Sajini Souda Senior Lecturer, Department of Pathology, Faculty of Medicine, University of Botswana, 
discussed recent findings regarding the use of prophylactic antibiotics to prevent surgical site 
infections (SSIs) in PMH in Gaborone, the principal public hospital in Botswana.  This prospective 
study involved 400 patients, with patients followed-up for 30 days post discharge to detect SSIs (21). 
The most common operations were exploratory laparotomy (25%), appendectomy (18.3%), excisions, 
and mastectomy (8%). Prophylactic antibiotics were given to 73.3% of patients; however, most were 
given post operatively (58.3%) with 15% commenced preoperatively, which is against current 
guidance. The most common antibiotics prescribed were cefotaxime (80.7%) and metronidazole 
(63.5%), with Pseudomonas aeruginosa, Staphylococcus aureus, and Escherichia coli were the most 
common organisms identified. The incidence of SSI was 9%, and interventions have already been put 
in place to try and reduce this (21).  
 
Tebogo Madidimalo from WHO Botswana (22) subsequently discussed ongoing global initiatives to 
help contain and reduce AMR, which is a growing concern with mortality estimated to increase to 10 
million deaths per year and global GDP reduce by 1 to 3.5% by 2050 if not addressed (10). In 
addition, at the UN General Assembly in 2016, all countries committed to preparing antimicrobial 
NAPs. The guiding principles include: (i) one-health approach including human health, animal health, 
and agriculture; (ii) prevention first; (iii) access not excess; (iv) sustainability; and (v) incremental 
targets for implementation. This initiative also includes improving awareness and understanding of 
AMR through education and training as well as simple measures such as hand hygiene, vaccination 
and improved sanitation. The next steps include approving the Botswana NAP. 
 
Celda Tiroyakgosi started by endorsing the WHO and UN initiatives followed by an update of current 
activities in Botswana to reduce AMR rates. Activities included attending a WHO AFRO workshop for 
the development of NAPs held in Zimbabwe 25th -27th January, 2017 which promoted the concept of 
µRQHKHDOWK¶. Since then Botswana has embarked on developing its NAP with a governance structure 
now in place, and there is increased monitoring of antimicrobial use via the Technical Working Groups 
(TWG). The National Health Policy and National Drug Policy spearhead the health of the population to 
ensure access to safe, effective and quality medicines. Structures in place to implement the National 
Drug Policy include the Medicines Regulation Authority, responsible for registration of safe, effective 
quality medicines; BEDAP (Botswana Essential Drugs Action Programme) which selects and ensures 
rational use of medicines; Central Medical Stores, which is responsible for selection, forecasting, 
procurement, storage, and distribution of medicines and NDQCL (National Drug Quality Control 
Laboratory) which is responsible for testing and quality control. The antimicrobial NAP builds on this. 
In addition, the Botswana EML and guidelines are being updated and Drug and Therapeutic 
Committees promoted in hospitals by the the Ministry of Health. Infection control committees and 
Antimicrobial Stewardship Programmes (ASPs) are also being established, and future antimicrobial 
prescribing monitored. 
 
Bene Paramadhas, Chief Pharmacist at Nyangabgwe Hospital, Botswana, together with Fatima 
Sinkala, Clinical Pharmacist Letsholathebe II memorial hospital, shared their experiences with 
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conducting PPS studies in Botswana. The data collection forms for the PPS study were adapted to 
include co-morbidities such as HIV, tuberculosis and malaria, which are appreciably more common in 
countries in sub-Saharan Africa than western countries (3, 7). They reported that 773 patients have 
been analysed to date with the majority being females (60.9%). Key co-morbidities included malaria 
(2.5%), malnourishment (5%), TB (25.4%) and HIV (40% of those tested were HIV positive with 85% 
on HAART). More than two thirds (70.6%) of admissions were for infectious diseases with a high 
proportion of HAIs among children and the elderly. A total of 982 antibiotics were prescribed with a 
high frequency of missed doses (mean of 1.96 per patient, SD = 4.17). The highest proportion of 
antibiotics prescribed were in tertiary (1.76/ patient) and specialist hospitals (1.42/ patient). 
Cefotaxime (20.3%), metronidazole (12.8%) and the penicillins (27.4%) were the most prescribed 
antibiotics, with variations between hospital types. Surgical patients received more than 1 day of 
prophylaxis in 66.7%, 100% and 90.3% of specialist, tertiary and district hospitals respectively. 
Injectable use was higher in specialist and tertiary hospitals, with variable ordering of culture and 
sensitivities (CSTs) despite functional microbiology labs, and typically no antibiograms to guide 
prescribing. Only 20% of hospitals currently had ASPs, and there was an appreciable lack of antibiotic 
guidelines (50%) and essential medicine lists (40%) in the wards in a number of settings. These 
concerns are being addressed. 
 
Brighid Malone, Family Physician at Bokamoso hospital, described some of the experiences in 
Bokamoso hospital (23). The PPS was undertaken on an atypical day where most patients admitted 
were either elective surgery or non-infectious medical patients. The study involved 57 patients (6 
others did not give their consent). There was no infectious diagnosis recorded for 73% of patients. 
Among those recorded, community acquired infection predominated (93%), with HIV status recorded 
in only 26% of patients despite the majority of patients in Botswana knowing their HIV status. Nearly 
all the antibiotics prescribed were on the Botswana EML, with 40% prescribed for prophylaxis and 
60% for treatment. 66% of antibiotics prescribed for prophylaxis were prescribed for longer than 24 
hours. There were concerns with missed doses (27%) as well as low rates of CST requests. These 
areas are being addressed.  
 
4. Conclusion and next steps 
Agreed next steps following this interactive symposium included submitting a number of the studies 
for potential publication including the PPS, SSI and private sector URTI studies. In addition, there is a 
proposal  to study on SSIs as well as hang-time in Bokamoso and other interested hospitals; 
undertaking the PPS study in PMH and other interested hospitals; and documenting the findings as 
part of Botswana NAP and IRB research activities. Additional activities proposed include instigating 
interventions to address areas of concern, instigating protected time to undertake ASPs, revising the 
current antibiotic guidelines, and monitoring subsequent antibiotic use against agreed guidance. In 
addition, the PPS data collection tools are being revised to improve collection of relevant data, 
potentially incorporating APPs (13).    
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